The Global Demand for Endometriosis Drugs is Projected to Reach US$2.6 Billion by 2022

Growing Awareness and Gradual Dissipation of the Stigma and Taboo Associated With the Condition to Drive the Global Endometriosis Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Endometriosis market. The global demand for Endometriosis Drugs is projected to reach US$2.6 billion by 2022, driven by the growing patient and social awareness, understanding and knowledge over the medical condition and the ensuing dissipation of the stigma associated with the disease; increased willingness to obtain medical help and the resulting drastic reduction in delayed diagnosis.

Endometriosis is one of the most common and under-diagnosed conditions in women due to its complex symptoms that may overlap with those of other conditions such as Irritable Bowel Syndrome and also due to gender issues, and myths and misconceptions about the disease. Endometriosis causes debilitating chronic pain, infertility, painful intercourse, depression, and amenorrhea; the disease accounts for significant global economic burden due to lost productivity of affected women. Endometriosis treatment is mainly dominated by pain medications, such as Non-Steroidal Anti Inflammatory Drugs (NSAIDs) and hormonal therapies, such as progestin treatment or contraceptive pills that reduce menstrual cycles. Abbvie’s Lupron and oral contraceptive pills (mostly by Bayer) have traditionally been used to treat endometriosis and its symptoms. However, these drugs are present with side-effects and usually are a stop-gap before surgery. Endometriosis also features a high rate of recurrence, which necessitates multiple surgeries. Extensive research is underway to decipher the exact causes of endometriosis, and develop drugs which offer long-term cure for the condition. Currently, more research efforts and hopes are focused on non-hormonal therapies for endometriosis.

The market in the coming years will benefit from the launch of Neurocrine and Abbvie’s Elagolix, the first oral GnRH (gonadotropin releasing hormone) antagonist superior to injectable GnRH agonists. Lupron (leuprolide acetate, by Abbott) is slated to lose its patent in 2016. This change is expected to be offset by the timely launch of Elagolix. The oral formulation of Elagolix enables dose administration and monitoring by the physician and is expected to minimize side-effects associated with GnRH agonists, such as hormonal flare effects and reduction of bone mineral density (BMD). Other late-stage pipeline drugs for endometriosis include Takeda’s TAK-385 (Relugolix), and Bayer’s BAY 98-7196.

As stated by the new market research report on Endometriosis, the United States represents the largest market worldwide. Asia-Pacific ranks as the fastest growing market with a CAGR of 3.4% over the analysis period, led by large population and unmet therapeutic needs for endometriosis, increasing awareness about the condition, and increasing healthcare spending among the growing base of affluent, middle class population.   

Major players covered in the report include AbbVie Inc., AEterna Zentaris Inc., Astellas Pharma Inc., AstraZeneca Plc., Bayer HealthCare Pharmaceuticals Inc., Debiopharm Group, Evotec AG, Kissei Pharmaceutical Co., Ltd., Neurocrine Biosciences Inc., ObsEva SA, Pfizer Inc., Repros Therapeutics Inc., Roivant Sciences Limited, Takeda Pharmaceutical Company Limited, and ValiRx Plc, among others.

The research report titled "Endometriosis: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, growth drivers, mergers and acquisitions, and other strategic industry activities of major companies worldwide. The report provides market estimates and projections for geographic markets, such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), Asia-Pacific, and Rest of World.  

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.